Literature DB >> 32227761

Chinese herbal medicine therapy for coronary heart disease complicated with anxiety: a systematic review of randomized controlled trials.

Chao Wang1, Jiqiu Hou2, Shasha Yan2, Lili Zhu2, Yun Wang2, Yun Wang2, Hongsen Du2, Wenzong Zhang3, Haibin Zhao1.   

Abstract

OBJECTIVE: To evaluated the effectiveness and safety of Chinese herbal medicines (CHMs) for coronary heart disease (CHD) complicated with anxiety.
METHODS: Randomized controlled clinical trials (RCTs) with parallel-groups were included after searching through electric-databases from inception to May, 2017. Meta-analysis was undertaken with RevMan 5.3 software.
RESULTS: Twenty-three RCTs enrolling 1654 patients were included in this systematic review. The combination therapy (CHMs combined with anxiolytic) appeared to be superior to anxiolytic in terms of reducing the score of Zung Self-rating Anxiety scale (SAS) (mean Difference (MD), -12.25; 95% confidence interval (CI), -14.01 to -10.48, eliminating method; MD, -3.92; 95% CI, -5.48 to -2.35, tranquilizing method), improving the total effect rate (relative risk (RR), 1.26; 95% CI, 1.08 to 1.46, eliminating method) and reducing the TCM symptoms scores (MD, -2.24; 95% CI, -4.25 to -0.23, tranquilizing method) with a lower incidence of adverse events (RR, 0.46; 95% CI, 0.25 to 0.85, tonifying method). CHMs demonstrated benefits in lowering the score of Hamilton Anxiety Rating scale (MD, -6.77; 95% CI, -8.16 to -5.37, tonifying method),lowering the score of SAS (MD, -10.1; 95% CI, -13.73 to -6.30, tonifying method) and reducing the TCM symptoms scores (MD, -2.18; 95% CI, -3.12 to -1.24, tranquilizing method).
CONCLUSION: We got a low evidence that CHMs,which had less side effects, showed potentially benefits to patients with CHD complicated with anxiety. While the results should be interpreted with caution. Trails with higher quality are required to verify the effectiveness and safety of CHMs for CHD complicated with anxiety.

Entities:  

Keywords:  Anxiety; Coronary disease; Drugs, Chinese herbal; Randomized controlled trial; Review

Mesh:

Substances:

Year:  2020        PMID: 32227761

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  3 in total

1.  Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.

Authors:  Ke Hu; Wei-Jie Guan; Ying Bi; Wei Zhang; Lanjuan Li; Boli Zhang; Qingquan Liu; Yuanlin Song; Xingwang Li; Zhongping Duan; Qingshan Zheng; Zifeng Yang; Jingyi Liang; Mingfeng Han; Lianguo Ruan; Chaomin Wu; Yunting Zhang; Zhen-Hua Jia; Nan-Shan Zhong
Journal:  Phytomedicine       Date:  2020-05-16       Impact factor: 5.340

2.  Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study.

Authors:  Jiaxing Tian; Shiyan Yan; Han Wang; Ying Zhang; Yujiao Zheng; Haoran Wu; Xiuyang Li; Zezheng Gao; Yanke Ai; Xiaowen Gou; Lei Zhang; Liyun He; Fengmei Lian; Baoyan Liu; Xiaolin Tong
Journal:  Pharmacol Res       Date:  2020-08-10       Impact factor: 7.658

Review 3.  The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis.

Authors:  Xufei Luo; Xiaojia Ni; Jiahui Lin; Yidan Zhang; Lei Wu; Donghui Huang; Yuntao Liu; Jianwen Guo; Wanxin Wen; Yefeng Cai; Yaolong Chen; Lin Lin
Journal:  Phytomedicine       Date:  2020-07-11       Impact factor: 5.340

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.